Alectinib
- Generic Name
- Alectinib
- Brand Names
- Alecensa, Alecensaro
- Drug Type
- Small Molecule
- Chemical Formula
- C30H34N4O2
- CAS Number
- 1256580-46-7
- Unique Ingredient Identifier
- LIJ4CT1Z3Y
- Background
Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ...
- Indication
Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this ...
- Associated Conditions
- Refractory, metastatic Non small cell lung cancer
- Associated Therapies
- -
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 342
- Registration Number
- NCT06709274
- Locations
- 🇨🇳
Dongguan People's Hospital, Dongguan, Guangdong, China
🇨🇳The First People's Hospital of Foshan, Foshan, Guangdong, China
🇨🇳Guangdong Provincial People's Hostpital, Guangzhou, Guangdong, China
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
- Conditions
- Interventions
- Drug: Albumin-Bound PaclitaxelDrug: OtherDrug: EpirubicinDrug: GemcitabineDrug: VinorelbineDrug: CisplatinDrug: IrinotecanDrug: FluorouracilDrug: NivolumabDrug: PembrolizumabDrug: DurvalumabDrug: AtezolizumabDrug: SintilimabDrug: TislelizumabDrug: CamrelizumabDrug: ToripalimabDrug: SerplulimabDrug: AdebrelimabDrug: EnvafolimabDrug: OsimertinibDrug: AlectinibDrug: VemurafenibDrug: PamiparibDrug: PyrotinibDrug: ImatinibDrug: PalbociclibDrug: SavolitinibDrug: Entrectinib
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Peking University Shenzhen Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06692491
A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 150
- Registration Number
- NCT06624059
- Locations
- 🇨🇱
Centro de Estudios Clínicos SAGA, Santiago, Chile
🇨🇱OrlandiOncología, Santiago, Chile
🇨🇱Inst. Nacional Del Cancer; Servicio de Oncologia Medica, Santiago, Chile
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 80
- Registration Number
- NCT06532149
- Locations
- 🇮🇹
Fondazione Policlinico Gemelli IRCCS, Rome, Italy
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Joshua Palmer
- Target Recruit Count
- 56
- Registration Number
- NCT05987644
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20605
- Registration Number
- NCT05834348
- Locations
- 🇳🇴
Pfizer Norway, Oslo, Norway
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 30
- Registration Number
- NCT05770037
- Locations
- 🇬🇧
Leeds General Infirmary, Leeds, United Kingdom
🇬🇧Royal Hospital for Children Glasgow, Glasgow, United Kingdom
🇬🇧Birmingham Children's Hospital, Birmingham, United Kingdom
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05725200
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 825
- Registration Number
- NCT05722886
- Locations
- 🇬🇧
Belfast City Hospital, Belfast, United Kingdom
🇬🇧Bristol Royal Hospital for Children, Bristol, United Kingdom
🇬🇧The Beatson Hospital, Glasgow, United Kingdom
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT05525858
- Locations
- 🇰🇷
Soonchunhyang University Hospital Bucheon, Bucheon, Korea, Republic of
🇰🇷Chungbuk National University Hospital, Chungju, Korea, Republic of
🇰🇷Keimyung University Dongsan Hospital, Daegu, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.